The endotoxin-lipoprotein hypothesis - An update

Archives of Medical Science

Volumn 3, Issue 4 SUPPL. A, 2007, Pages

  Sandek, Anja ^a   Utchill, Stefanie ^a   Rauchhaus, Mathias ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cholesterol; Endotoxin; Heart failure; Immune activation; Lipids; LPS; Pathophysiology

Indexed keywords

ATORVASTATIN; BACTERIUM LIPOPOLYSACCHARIDE; CARVEDILOL; LOSARTAN; PLACEBO; ROSUVASTATIN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG INHIBITION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; INTESTINE ISCHEMIA; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; PATHOPHYSIOLOGY; PLEIOTROPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STROKE; THROMBOGENESIS; ULCERATIVE COLITIS;

EID: 39449117630     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Rauchhaus M, Clark AL, Doehner W, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003; 42: 1933-40.
2. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002; 8: 216-24.
3. Richartz BM, Radovancevic B, Frazier OH, Vaughn WK, Taegtmeyer H. Low serum cholesterol levels predict high perioperative mortality in patients supported by a left-ventricular assist system. Cardiology 1998; 89: 184-8.
4. Velavan P, Huan Loh P, Clark A, Cleland JG. The cholesterol paradox in heart failure. Congest Heart Fail 2007; 13: 336-41.
5. Horwich TB, Fonarow GC. Reverse epidemiology beyond dialysis patients: chronic heart failure, geriatrics, rheumatoid arthritis, COPD, and AIDS. Semin Dial 2007; 20: 549-53.
6. Poehlman ET, Scheffers J, Gottlieb SS, Fisher ML, Vaitekevicius P. Increased resting metabolic rate in patients with congestive heart failure. Ann Intern Med 1994; 121: 860-2.
7. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure: the importance for cardiac cachexia. Circulation 1997; 96: 526-34.
8. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000; 356: 930-3.
9. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236-41.
10. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001; 103: 2055-9.
11. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996; 27: 1201-6.
12. Rauchhaus M, Müller-Werdan U. Cytokines in heart diseases. Internist 2001; 42: 75-84.
13. Shan K, Kurrelmeyer K, Seta Y, et al. The role of cytokines in disease progression in heart failure. Curr Opin Cardiol 1997; 12: 218-23.
14. Devaux B, Scholz D, Hirche A, Klövekorn WP, Schaper J. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J 1997; 18: 470-9.
15. Hasper D, Hummel M, Kleber FX, Reindl I, Volk HD. Systemic inflammation in patients with heart failure. Eur Heart J 1998; 19: 761-5.
16. Müller-Werdan U, Werdan K. Immune modulation by catecholamines - a potential mechanism of cytokine release in heart failure? Herz 2000; 25: 271-3.
17. Jankowska EA, Ponikowski P, Piepoli MF, Banasiak W, Anker SD, Poole-Wilson PA. Autonomic imbalance and immune activation in chronic heart failure - pathophysiological links. Cardiovasc Res 2006; 70: 434-45.
18. Anker SD, Egerer KR, Volk HD, Kox WJ, Poole-Wilson PA, Coats AJ. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 1997; 79: 1426-30.
19. Genth-Zotz S, von Haehling S, Bolger AP, et al. Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. Am J Cardiol 2002; 90: 1226-30.
20. Koloczek V, Rauchhaus M, Crane R, et al. Markers of intestinal ischaemia relate to immune activation in chronic heart failure. Circulation 1999; 100 (Suppl): 1-206.
21. Peschel T, Schonauer M, Thiele H, Anker SD, Schuler G, Niebauer J. Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. Eur J Heart Fail 2003; 5: 609-14.
22. Sandek A, Bauditz J, Swidsinski A, et al. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 1561-9.
23. Takala J. Determinants of splanchnic blood flow. Br J Anaesth 1997; 77: 50-8.
24. Gutierrez G, Palizas F, Doglio G, et al. Gastric intramucosal pH as a therapeutic index of tissue oxygination in critically ill patients. Lancet 1992; 339: 195-9.
25. Maynard N, Bihari D, Beale R, et al. Assessment of splanchnic oxygenation by gastric tonometry in patients with acute circulatory failure. JAMA 1993; 270: 1203-10.
26. Boyd O, Mackay C, Lamb G, et al. Comparison of clinical information gained from routine blood-gas analysis and from gastric tonometry for intramural pH. Lancet 1993; 341: 142-6.
27. Krack A, Sharma R, Figulla HR, Anker SD. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J 2005; 26: 2368-74.
28. Conraads VM, Jorens PG, De Clerck LS, et al. Selective intestinal decontamination in advanced chronic heart failure: a pilot trial. Eur J Heart Fail 2004; 6: 483-91.
29. King D, Smith ML, Chapman TJ, Stockdale HR, Lye M. Fat malabsorption in elderly patients with cardiac cachexia Age Ageing 1996; 25: 144-9.
30. Davidson JD, Waldmann TA, Goodman DS, Gordon RS. Protein-losing gastroenteropathy in congestive heart-failure. Lancet 1961; 1: 899-902.
31. Kitz R, Rose MA, Placzek K, Schulze J, Zielen S, Schubert R. LPS inhalation challenge: a new tool to characterize the inflammatory response in humans. Med Microbiol Immunol 2008; 197: 13-9.
32. Kitz R, Rose MA, Borgmann A, Schubert R, Zielen S. Systemic and bronchial inflammation following LPS inhalation in asthmatic and healthy subjects. J Endotoxin Res 2006; 12: 367-74.
33. Michel O, Nagy AM, Schroeven M, et al. Dose-response relationship to inhaled endotoxin in normal subjects. Am J Respir Crit Care Med 1997; 156: 1157-64.
34. Anker SD, Ponokowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997; 349: 1050-3.
35. Von Haehling S, Doehner W, Anker SD. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res 2007; 73: 298-309.
36. Anker SD, Ponikowski PP, Clark AL, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J 1999; 20: 683-93.
37. Anker SD, Clark AL, Kemp M, et al. Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J Am Coll Cardiol 1997; 30: 997-1001.
38. Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999; 353: 1838-42.
39. Rauchhaus M, Koloczek V, Volk H, Kemp M, Niebauer J, Francis DP, Coats AJ, Anker SD. Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol 2000; 76: 125-33.
40. Wang Ch-Y, Liao JK. Current advances in statin treatment: from molecular mechanisms to clinical practice. Arch Med Sci 2007; 3(4A): 91-6.
41. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000; 102: 3060-7.
42. Sakai H, Hisamoto S, Fukutomi I, Sou K, Takeoka S, Tsuchida E. Detection of lipopolysaccharide in hemoglobin-vesicles by Limulus amebocyte lysate test with kinetic-turbidimetric gel clotting analysis and pretreatment of surfactant. J Pharm Sci 2004; 93: 310-21.
43. Williams KL. Endotoxins - pyrogenes, LAL-Testing, and depyrogenisation. In: Drugs and the Pharmaceutical Sciences, Volume 111, Second Edition. Marcel Dekker Inc. USA; 2001.
44. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol 1998; 274: R577-95.
45. Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M, Mann DL. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 1997; 95: 1247-52.
46. Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor α- induced apoptosis in cardiac myocytes: involvement of the sphingolipid signalling cascade in cardiac cell death. J Clin Invest 1996; 98: 2854-65.
47. Langhans W, Hrupka B. Interleukins and tumor necrosis factor as inhibitors of food intake. Neuropeptides 1999; 33: 415-24.
48. Müller-Werdan U, Werdan K. Immune modulation by catecholamines - a potential mechanism of cytokine release in heart failure? Herz 2000; 25: 271-3.
49. Werner C., Werdan K, Pönicke K, Brodde OE. Impaired beta-adrenergic control of immune function in patients with chronic heart failure: reversal by beta1-blocker treatment. Basic Res Cardiol 2000; 96: 290-8.
50. Flierl MA, Rittirsch D, Nadeau BA, et al. Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature 2007; 449: 721-5.
51. Triantafilou M, Triantafilou K. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol 2002; 23: 301-4.
52. da Silva Correia J, Soldau K, Christen U, Tobias PS, Ulevitch RJ. Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex, transfer from CD14 to TLR4 and MD-2. J Biol Chem 2001; 276: 21129-35.
53. Page CP, Curtis MJ, Sutter MC, Walker MJ, Hoffman BB. Integrated Pharmacology. Mosby, London, Chicago 1997; 267-70.
54. Genth-Zotz S, Bolger AP, Kalra PR, et al. Heat shock protein 70 in patients with chronic heart failure: relation to disease severity and survival. Int J Cardiol 2004; 96: 397-401.
55. Kälsch T, Elmas E, Nguyen XD, et al. Endotoxin-induced effects on platelets and monocytes in an in vivo model of inflammation. Basic Res Cardiol 2007; 102: 460-6.
56. Osterud B. Tissue factor expression by monocytes: regulation and pathophysiological roles. Blood Coagul Fibrinolysis 1998; 9: 9-14.
57. Steiner S, Speidl WS, Pleiner J, et al. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 2005; 111: 1841-6.
58. Chin BS, Blann AD, Gibbs CR, Chung NA, Conway DG, Lip GY. Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur J Clin Invest 2003; 33: 941-8.
59. Mizuochi Y, Okajima K, Harada N, et al. Carvedilol, a nonselective beta-blocker, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro. Transl Res 2007; 149: 223-30.
60. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106: 2194-9.
61. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. International Journal of Cardiology 2002; 86: 123-30.
62. Axtelle T, Pribble J. IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis. J Endotoxin Res 2001; 7: 310-4.
63. Verbon A, Dekkers PE, ten Hove T, et al. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol 2001; 166: 3599-605.
64. Genth-Zotz S, von Haehling S, Bolger AP, et al. The anti-CD14 antibody IC14 suppresses ex vivo endotoxin stimulated tumor necrosis factor-alpha in patients with chronic heart failure. Eur J Heart Fail 2006; 8: 366-72.
65. Parlesak A, Schaeckeler S, Moser L, Bode C. Conjugated primary bile salts reduce permeability of endotoxin through intestinal epithelial cells and synergize with phosphatidylcholine in suppression of inflammatory cytokine production. Crit Care Med 2007; 35: 2367-74.
66. Harris H, Grunfeld C, Feingold K, Rapp J. Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest 1990; 86: 696-702.
67. Flegel WA, Baumstark MW, Weinstock C, Berg A, Northoff H. Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. Infect Immun 1993; 61: 5140-6.
68. Netea MG, de Bont N, Demacker PN, et al. Lipoprotein(a) inhibits lipopolysaccharide-induced tumor necrosis factor alpha production by human mononuclear cells. Infect Immun 1998; 66: 2365-7.
69. Parker TS, Levine TM, Chang JC, Laxer J, Coffin CC, Rubin AL. Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood. Infect Immun 1995; 63: 253-8.
70. Emancipator K, Csako G, Elin RJ. In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins. Infect Immun 1992; 60: 596-601.
71. Pajkrt D, Doran JE, Koster F, et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996; 184: 1601-8.
72. Birjmohun RS, van Leuven SI, Levels JH, et al. High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans. Arterioscler Thromb Vasc Biol 2007; 27: 1153-8.
73. Sharma R, von Haehling S, Rauchhaus M, et al. Whole blood endotoxin responsiveness in patients with chronic heart failure: the importance of serum lipoproteins. Eur J Heart Fail 2005; 7: 479-84.
74. Englund MC, Karlsson AK, Wiklund O, Bondjers G, Ohlsson BG. 25-hydroxycholesterol induces lipopolysaccharide-tolerance and decreases a lipopolysaccharide-induced TNF-alpha secretion in macrophages. Atherosclerosis 2001; 158: 61-71.
75. Sharma R, Bolger AP, Rauchhaus M, et al. Cellular endotoxin desensitization in patients with severe chronic heart failure. Eur J Heart Fail 2005; 7: 865-8.
76. Mayer K, Gokorsch S, Fegbeutel C, et al. Parenteral nutrition with fish oil modulates cytokine response in patients with sepsis. Am J Respir Crit Care Med 2003; 167: 1321-8.
77. Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear celts. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989; 320: 265-71.
78. Caughey GE, Mantzioris E, Gibson RA, Cleland LG, James MJ. The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr 1996; 63: 116-22.
79. Caradonna L, Amati L, Lella P, Jirillo E, Caccavo D. Phagocytosis, killing, lymphocyte-mediated antibacterial activity, serum autoantibodies, and plasma endotoxins in inflammatory bowel disease. Am J Gastroenterol 2000; 95: 1495-502.
80. Harris HW, Grunfeld C, Feingold KR, et al. Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death. J Clin Invest 1993; 91: 1028-34.
81. Wendel M, Paul R, Heller AR. Lipoproteins in inflammation and sepsis. II. Clinical aspects. Intensive Care Med 2007; 33: 25-35.
82. Schatz IJ, Masaki K, Yano K, Chen R, Rodriguez BL, Curb JD. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 2001; 358: 351-5.
83. Gordon BR, Parker TS, Levine DM, et al. Relationship of hypolipidemia to cytokine concentrations and outcomes in critically ill surgical patients. Crit Care Med 2001; 29: 1563-8.
84. Chien JY, Jerng JS, Yu CJ, Yang PC. Low serum level of high-density lipoprotein is a poor prognostic factor for severe sepsis. Crit Care Med 2005; 33: 1688-93.
85. Iribarren C, Jacobs, DR Jr, Sidney S, Claxton AJ, Feingold KR. Cohort study of serum total cholesterol and in-hospital incidence of infectious diseases. Epidemiol Infect 1998; 121: 335-47.
86. Mimura Y, Sakisaka S, Harada M, Sata M, Tanikawa K. Role of hepatocytes in direct clearance of lipopolysaccharide in rats. Gastroenterology 1995; 109: 1969-76.
87. Ghermay AP, Brady S, Havel RJ, Harris HW, Rapp JH. Sepsis increases endocytosis of endotoxin into hepatocytes. Surgery 1996; 120: 389-94.
88. Spitzer AL, Harris HW. Statins attenuate sepsis. Surgery. 2006; 139: 283-7.
89. Harris HW, Kasravi FB. Lipoprotein-bound LPS induces cytokine tolerance in hepatocytes. J Endotoxin Res 2003; 9: 45-50.
90. Inoue I, Goto S, Mizotani K, et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 2000; 67: 863-76.
91. Földes G, von Haehling S, Okonko DO, Jankowska EA, Poole-Wilson PA, Anker SD. Fluvastatin reduces increased blood monocyte Toll-like receptor 4 expression in whole blood from patients with chronic heart failure. Int J Cardiol 2007 Mar 23 [Epub ahead of print].
92. Böhm M, Hjalmarson A, Kjekshus J, Laufs U, McMurray J, van Veldhuisen DJ. Heart failure and statins - why do we need a clinical trial? Z Kardiol 2005; 94: 223-30.
93. Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med 2000; 132: 636-40.
94. Soja AM, Mortensen SA. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol Aspects Med 1997; 18: 159-68.
95. Mortensen SA. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of "Q-symbio" - a multinational trial. Biofactors 2003; 18: 79-89.
96. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyörälä K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997; 3: 249-54.
97. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003; 108: 839-43.
98. Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006; 47: 332-7.
99. Hognestad A, Dickstein K, Myhre E, Snapinn S, Kjekshus J; OPTIMAAL Investigators. Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. Am J Cardiol 2004; 93: 603-6.
100. Hunt SA, American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005; 46: e1-82.
101. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-61.
102. Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111: 2356-63.